Loading...

Brent Kuenzi

Title(s)Postdoctoral Scholar, Medicine
SchoolVc-health Sciences-schools
Address9500 Gilman Drive #
La Jolla CA 92093
vCardDownload vCard

    Collapse Research 
    Collapse Research Activities and Funding
    New therapeutic opportunities from mining polypharmacology mechanisms of ceritinib in ALK-negative non-small cell lung cancer
    NIH/NCI K00CA212456Sep 19, 2016 - May 31, 2022
    Role: Principal Investigator
    New therapeutic opportunities from mining polypharmacology mechanisms of ceritinib in ALK-negative non-small cell lung cancer
    NIH/NCI F99CA212456Sep 19, 2016 - Aug 31, 2018
    Role: Principal Investigator

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Predicting Drug Response and Synergy Using a Deep Learning Model of Human Cancer Cells. Cancer Cell. 2020 Oct 21. Kuenzi BM, Park J, Fong SH, Sanchez KS, Lee J, Kreisberg JF, Ma J, Ideker T. PMID: 33096023.
      View in: PubMed   Mentions:    Fields:    
    2. A census of pathway maps in cancer systems biology. Nat Rev Cancer. 2020 04; 20(4):233-246. Kuenzi BM, Ideker T. PMID: 32066900.
      View in: PubMed   Mentions:    Fields:    Translation:HumansAnimalsCells
    3. An immunoproteomic approach to characterize the CAR interactome and signalosome. Sci Signal. 2019 02 12; 12(568). Ramello MC, Benzaïd I, Kuenzi BM, Lienlaf-Moreno M, Kandell WM, Santiago DN, Pabón-Saldaña M, Darville L, Fang B, Rix U, Yoder S, Berglund A, Koomen JM, Haura EB, Abate-Daga D. PMID: 30755478.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansAnimalsCells
    4. Off-target based drug repurposing opportunities for tivantinib in acute myeloid leukemia. Sci Rep. 2019 01 24; 9(1):606. Kuenzi BM, Remsing Rix LL, Kinose F, Kroeger JL, Lancet JE, Padron E, Rix U. PMID: 30679640.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCells
    5. The Galaxy Platform for Reproducible Affinity Proteomic Mass Spectrometry Data Analysis. Methods Mol Biol. 2019; 1977:249-261. Stewart PA, Kuenzi BM, Mehta S, Kumar P, Johnson JE, Jagtap P, Griffin TJ, Haura EB. PMID: 30980333.
      View in: PubMed   Mentions:    Fields:    
    6. Targeting the BRD4-HOXB13 Coregulated Transcriptional Networks with Bromodomain-Kinase Inhibitors to Suppress Metastatic Castration-Resistant Prostate Cancer. . 2018 12; 17(12):2796-2810. Nerlakanti N, Yao J, Nguyen DT, Patel AK, Eroshkin AM, Lawrence HR, Ayaz M, Kuenzi BM, Agarwal N, Chen Y, Gunawan S, Karim RM, Berndt N, Puskas J, Magliocco AM, Coppola D, Dhillon J, Zhang J, Shymalagovindarajan S, Rix U, Kim Y, Perera R, Lawrence NJ, Schonbrunn E, Mahajan K. PMID: 30242092.
      View in: PubMed   Mentions:
    7. Functional Proteomics and Deep Network Interrogation Reveal a Complex Mechanism of Action of Midostaurin in Lung Cancer Cells. Mol Cell Proteomics. 2018 12; 17(12):2434-2447. Ctortecka C, Palve V, Kuenzi BM, Fang B, Sumi NJ, Izumi V, Novakova S, Kinose F, Remsing Rix LL, Haura EB, Koomen JM, Rix U. PMID: 30217950.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCells
    8. Unraveling the rewired network. Nat Chem Biol. 2018 08; 14(8):746-747. Palve V, Kuenzi BM, Rix U. PMID: 29942077.
      View in: PubMed   Mentions:    Fields:    
    9. Ceritinib Enhances the Efficacy of Trametinib in BRAF/NRAS-Wild-Type Melanoma Cell Lines. . 2018 01; 17(1):73-83. Verduzco D, Kuenzi BM, Kinose F, Sondak VK, Eroglu Z, Rix U, Smalley KSM. PMID: 29133622.
      View in: PubMed   Mentions:
    10. Polypharmacology-based ceritinib repurposing using integrated functional proteomics. Nat Chem Biol. 2017 Dec; 13(12):1222-1231. Kuenzi BM, Remsing Rix LL, Stewart PA, Fang B, Kinose F, Bryant AT, Boyle TA, Koomen JM, Haura EB, Rix U. PMID: 28991240.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansCells
    11. Escape Excel: A tool for preventing gene symbol and accession conversion errors. PLoS One. 2017; 12(9):e0185207. Welsh EA, Stewart PA, Kuenzi BM, Eschrich JA. PMID: 28953918.
      View in: PubMed   Mentions:    Fields:    
    12. Sustained activation of the AKT/mTOR and MAP kinase pathways mediate resistance to the Src inhibitor, dasatinib, in thyroid cancer. Oncotarget. 2017 Nov 28; 8(61):103014-103031. Mishall KM, Beadnell TC, Kuenzi BM, Klimczak DM, Superti-Furga G, Rix U, Schweppe RE. PMID: 29262541.
      View in: PubMed   Mentions:    Fields:    
    13. Proteome-wide Profiling of Clinical PARP Inhibitors Reveals Compound-Specific Secondary Targets. Cell Chem Biol. 2016 Dec 22; 23(12):1490-1503. Knezevic CE, Wright G, Rix LLR, Kim W, Kuenzi BM, Luo Y, Watters JM, Koomen JM, Haura EB, Monteiro AN, Radu C, Lawrence HR, Rix U. PMID: 27866910.
      View in: PubMed   Mentions: 23     Fields:    
    14. APOSTL: An Interactive Galaxy Pipeline for Reproducible Analysis of Affinity Proteomics Data. J Proteome Res. 2016 12 02; 15(12):4747-4754. Kuenzi BM, Borne AL, Li J, Haura EB, Eschrich SA, Koomen JM, Rix U, Stewart PA. PMID: 27680298.
      View in: PubMed   Mentions: 7     Fields:    
    15. Chemoproteomics Reveals Novel Protein and Lipid Kinase Targets of Clinical CDK4/6 Inhibitors in Lung Cancer. ACS Chem Biol. 2015 Dec 18; 10(12):2680-6. Sumi NJ, Kuenzi BM, Knezevic CE, Remsing Rix LL, Rix U. PMID: 26390342.
      View in: PubMed   Mentions: 29     Fields:    Translation:HumansCells
    16. GSK3 alpha and beta are new functionally relevant targets of tivantinib in lung cancer cells. ACS Chem Biol. 2014 Feb 21; 9(2):353-8. Remsing Rix LL, Kuenzi BM, Luo Y, Remily-Wood E, Kinose F, Wright G, Li J, Koomen JM, Haura EB, Lawrence HR, Rix U. PMID: 24215125.
      View in: PubMed   Mentions: 37     Fields:    Translation:HumansCells
    Brent's Networks
    Concepts (100)
    Derived automatically from this person's publications.
    _
    Co-Authors (2)
    People in Profiles who have published with this person.
    _
    Similar People (60)
    People who share similar concepts with this person.
    _
    Same Department
    Search Department
    _